Evidence map›Paper›PMID 41301629›Full record

ReviewAntibiotics (Basel, Switzerland)2025

Phage Therapy for

Yilin Wang, Liuyan Li, Yuqi Liang, Kehan Xu, Ying Ye, Maozhang He

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Virulence · 2026
    Review
  2. Review
  3. Genomic landscape of 340 virulent Acinetobacter bacteriophages reveals anti-CRISPR-enriched candidates for therapeutic prioritization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  4. New Insights intoPathogens (Basel, Switzerland) · 2026
    Review
  5. Article
  6. Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  7. Review
  8. Review
  9. Advances in phage therapy forFrontiers in microbiology · 2026
    Review
  10. Bacteriophages targetingFrontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yilin WangThe Second Clinical School of Medicine, Anhui Medical University, Hefei 230032, China.ORCID 0009-0008-6175-9594
Liuyan LiThe Second Clinical School of Medicine, Anhui Medical University, Hefei 230032, China.ORCID 0009-0006-5987-4994
Yuqi LiangDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
Kehan XuDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
Ying YeThe First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Maozhang HeDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.ORCID 0000-0002-0743-7323

Funding

Anhui Provincial National Science Foundation 2308085QH283Basic and Clinical Collaboration Enhancement Program Foundation of Anhui Medical University 2022xkjT012National Natural Science Foundation of China 82302568
6 · The paper itself

Abstract

The global spread of carbapenem-resistant

Indexed as

antibiotic resistancebacteriophage classificationCRAB infectiongenetic engineeringphage cocktail therapies

Identifiers

PMID41301629
PMCPMC12649759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.